- STAT+: Three questions with Whoop’s new CMOIn this edition of STAT Health Tech: A chat with Whoop's new chief medical officer, an update on CMS health tech initiative, and more.
- Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…